-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Ambrx Biopharma Cayman, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2022 to 2023.
- Ambrx Biopharma Cayman, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2023 was $305 K, a 136% increase year-over-year.
- Ambrx Biopharma Cayman, Inc. annual Income Tax Expense (Benefit) for 2022 was $1.94 M, a 193600% increase from 2021.
- Ambrx Biopharma Cayman, Inc. annual Income Tax Expense (Benefit) for 2021 was $1 K, unchanged from 2020.
- Ambrx Biopharma Cayman, Inc. annual Income Tax Expense (Benefit) for 2020 was $1 K.
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)